Project description
First blood biomarker for assessment of mortality rate in cardiac arrhythmia
Among deaths caused by cardiovascular diseases around half are a result of ventricular arrhythmias causing sudden cardiac arrest. The diagnosis of arrhythmia is especially important for heart failure patients. Cardiologists urgently need accurate biomarkers for stratification of high-risk patients to treat them efficiently in cases of life-threatening arrhythmia. EU provided additional funding to finalise the development and bring to market a diagnostic test to measure the blood level of secretoneurin. This is a new biomarker for accurate risk stratification of patients with arrhythmia. The new test will enable the timely identification of high-risk patients who can then undergo life-saving implantable cardioverter-defibrillator surgery.
Objective
Cardiovascular disease (CVD) is the no. 1 killer worldwide. At least half of CVD deaths is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival, being more frequent and carrying greater risk in heart failure (HF) patients. When managing HF patients, cardiologists currently prescribe an ECG (which may detect an arrhythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.34 B€ overtreatment cost/year in the EU alone. Cardiologists urgently need an accurate biomarker that helps to better stratify patients’ risk for life-threatening arrhythmia. Existing cardiac biomarkers do not provide that info, keeping under or overtreatment.
CardiNor has IPR rights and is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a new biomarker that provides unmatched insight into the mechanisms of arrhythmia, with a prognostic capacity to accurately stratify the patients into risk categories. With SN data, cardiologists will be able to rightly pinpoint high-risk patients and select those patients to ICD surgery. For every 10% of ICD-eligible patients that are diverted from surgery more than 134M€ are saved every year. First sales will be in 2020 as an ELISA kit and over time added to other IVD platforms to increase exploitation potential. CardiNor and its value chain partners have been working together on the SN assay for 24+ months, having reached TRL6 in Q3 2018.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
0349 Oslo
Norway
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.